Douglas Lorne Arnold, MD, FRCP(C)

Cited by

	All	Since 2018
Citations	54977	22437
h-index	121	65
i10-index	402	291

4300

2150

1075

3225

199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023164 145 178 219 294 292 446 531 704 813 1093 1125 1065 1186 1358 1211 1278 1307 1312 1391 1335 1691 1952 2169 2339 2675 3001 3118 3333 3576 4225 4138 3879

Public access

View all

99 articles

29 articles

available

not available

Based on funding mandates

Co-authors

Sridar Narayanan, PhDAssistant Professor: Department of Neurology and Neurosurgery, McGill UniversityVerified email at mcgill.ca
Amit Bar-OrProfessor, University of PennsylvaniaVerified email at pennmedicine.upenn.edu
Paul M. MatthewsEdmond and Lily Safra Chair, Professor of Clinical Neurosciences, Imperial College LondonVerified email at imperial.ac.uk
D. Louis CollinsProfessor of Biomedical Engineering and Neurology & Neurosurgery, McGill UniversityVerified email at mcgill.ca
Nicola De StefanoProfessor of Neurology, Universtiy of Siena,Verified email at unisi.it
Gavin GiovannoniBarts and The London School of Medicine and DentistryVerified email at giovannoni.net
Zografos CaramanosMcConnell Brain Imaging Centre, Montreal Neurological Institute, McGill UniversityVerified email at mcgill.ca
Jerry S Wolinsky, MDEmeritus Professor in Neurology, McGovern Medical School, UTHealth, The University of Texas HealthVerified email at uth.tmc.edu
Fernando CendesFull Professor, Department of Neurology, FCM, University of Campinas - UNICAMPVerified email at unicamp.br
Jeffrey A CohenCleveland ClinicVerified email at ccf.org
Robert J FoxMellen Center for Multiple Sclerosis, Cleveland ClinicVerified email at ccf.org
eric shoubridgeProfessor, Human Genetics, McGill UniversityVerified email at ericpc.mni.mcgill.ca
Li Min LiProfessor of Neurology, Faculty of Medical Sciences at University of CampinasVerified email at fcm.unicamp.br
Robert A BrownUniversity of Calgary; Montreal Neurological Institute; ShadowLab Research Inc.Verified email at shadowlabresearch.com
John G. SledSenior Scientist, Hospital for Sick Children / Professor, University of TorontoVerified email at utoronto.ca
Bruce PikeCAIP Chair in Healthy Brain Aging, Head of Image Science, Professor - U of CalgaryVerified email at ucalgary.ca
Emmanuelle WaubantProfessor of Neurology and PediatricsVerified email at ucsf.edu
Alasdair ColesUniversity of CambridgeVerified email at medschl.cam.ac.uk
Carmela TartagliaAssociate Professor, University of TorontoVerified email at uhn.ca
Tal ArbelProfessor of Electrical & Computer Engineering, McGill UniversityVerified email at cim.mcgill.ca

Douglas Lorne Arnold, MD, FRCP(C)

James McGill Professor: Department of Neurology and Neurosurgery, Faculty of Medicine, McGill

Verified email at mcgill.ca - Homepage

Magnetic Resonance Imaging Neurological Disorders Multiple Sclerosis Alzheimer's Disease


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
B-cell depletion with rituximab in relapsing–remitting multiple sclerosis SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, RJ Fox, A Bar-Or, ... New England Journal of Medicine 358 (7), 676-688, 2008	2658	2008
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni, K Selmaj, ... New England Journal of Medicine 367 (12), 1098-1107, 2012	1967	2012
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... N Engl J Med 376 (3), 209-220, 2017	1766	2017
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis SL Hauser, A Bar-Or, G Comi, G Giovannoni, HP Hartung, B Hemmer, ... N Engl J Med 376 (3), 221-234, 2017	1558	2017
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial AJ Coles, CL Twyman, DL Arnold, JA Cohen, C Confavreux, EJ Fox, ... The lancet 380 (9856), 1829-1839, 2012	1211	2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial JA Cohen, AJ Coles, DL Arnold, C Confavreux, EJ Fox, HP Hartung, ... The Lancet 380 (9856), 1819-1828, 2012	1204	2012
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P ... Lancet 391 (10127), 1263-1273, 2018	872	2018
Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy MC Preul, Z Caramanos, DL Collins, JG Villemure, R Leblanc, A Olivier, ... Nature medicine 2 (3), 1996	665	1996
Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability N De Stefano, S Narayanan, GS Francis, R Arnaoutelis, MC Tartaglia, ... Archives of neurology 58 (1), 65-70, 2001	651	2001
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: Results of a longitudinal magnetic resonance spectroscopy study N De Stefano, PM Matthews, L Fu, S Narayanan, J Stanley, GS Francis, ... Brain 121 (Pt 8), 1469-1477, 1998	608	1998
Imaging axonal damage of normal-appearing white matter in multiple sclerosis L Fu, PM Matthews, N De Stefano, KJ Worsley, S Narayanan, GS Francis, ... Brain 121 (1), 103-113, 1998	602	1998
Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial A Bar‐Or, PAJ Calabresi, D Arnold, C Markowitz, S Shafer, LH Kasper, ... Annals of neurology 63 (3), 395-400, 2008	590	2008
Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI study of the hippocampus, amygdala and parahippocampal region N Bernasconi, A Bernasconi, Z Caramanos, SB Antel, F Andermann, ... Brain 126 (2), 462-469, 2003	570	2003
Metabolic recovery after exercise and the assessment of mitochondrial function in vivo in human skeletal muscle by means of 31P NMR DL Arnold, PM Matthews, GK Radda Magnetic resonance in medicine 1 (3), 307-315, 1984	565	1984
Reversible decreases in N‐acetylaspartate after acute brain injury ND Stefano, PM Matthews, DL Arnold Magnetic Resonance in Medicine 34 (5), 721-727, 1995	532	1995
Review of automatic segmentation methods of multiple sclerosis white matter lesions on conventional magnetic resonance imaging D Garcia-Lorenzo, S Francis, S Narayanan, DL Arnold, DL Collins Medical image analysis 17 (1), 1-18, 2013	436	2013
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study PA Calabresi, BC Kieseier, DL Arnold, LJ Balcer, A Boyko, J Pelletier, ... The Lancet Neurology 13 (7), 657-665, 2014	425	2014
Exploring uncertainty measures in deep networks for Multiple sclerosis lesion detection and segmentation AT Nair T, Precup D, Arnold DL Med Image Anal 59, 101557, 2020	408	2020
Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques DL Arnold, PM Matthews, GS Francis, J O'Connor, JP Antel Annals of Neurology: Official Journal of the American Neurological …, 1992	395	1992
Chemical pathology of acute demyelinating lesions and its correlation with disability N De Stefano, PM Matthews, JP Antel, M Preul, G Francis, DL Arnold Annals of neurology 38 (6), 901-909, 1995	389	1995

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors